# Danish pharmaceutical company Zealand Pharma reported a less-than-expected operating loss for the first quarter of the year.

*biotech · news · 2026-05-07 · Devdiscourse*

## Key points

- Zealand Pharma reported a smaller-than-expected Q1 operating loss of 539 million Danish crowns.
- The company announced a $200 million share buyback, indicating a positive future outlook.
- Zealand expects $700 million from a partnership with Roche tied to petrelintide's Phase 3 trial.
- Advances in Zealand's obesity drug pipeline drove better-than-forecast results for the quarter.

**Companies:** Zealand Pharma
**Countries:** Denmark, Switzerland

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/headlines/3899503-zealand-pharma-surprises-with-smaller-loss-and-bold-200m-share-buyback)

---

Canonical: https://newsio.io/n/74bcc8b8-e25e-4731-8e9a-0a10cc42bf90/danish-pharmaceutical-company-zealand-pharma-reported-a-less-than-expected-opera
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works